Catalyst Funds Management Pty LTD Protalix Bio Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 10,200 shares of PLX stock, worth $13,362. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,200Holding current value
$13,362% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PLX
# of Institutions
49Shares Held
3.9MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$1.25 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$570,1290.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$489,6210.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$436,4540.0% of portfolio
-
Jane Street Group, LLC New York, NY290KShares$380,2390.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $65.2M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...